Breaking Down Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. Financial Health: Key Insights for Investors

Sinopep-Allsino's latest financial snapshot packs striking contrasts that every investor should parse: quarterly revenue surged to CNY 478.90 million (up 13.82% QoQ) driving a trailing twelve-month revenue of CNY 1.90 billion and 2024 annual sales of CNY 1.62 billion (a 57.21% jump year-over-year), while profitability remains robust with a net profit margin of 26.25% and EBITDA of CNY 662.75 million-yet market valuation and risk metrics warrant scrutiny, from a market cap near CNY 12.22 billion and P/E of 24.59 to a debt-to-equity ratio of 82.43% and total debt of CNY 2.58 billion; investors must weigh solid liquidity (cash CNY 988.01 million, current ratio ~1.5, operating cash flow CNY 517.18 million) and growth levers like heavy R&D and portfolio expansion against regulatory shocks including a CNY 47.4 million fine and a delisting warning in July 2025-read on for a line-by-line breakdown of revenue, margins, leverage, valuation, and the upside risks that could redefine the stock's trajectory.

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS) - Revenue Analysis

• Q3 2025 revenue: CNY 478.90 million (q/q +13.82%)
• TTM revenue: CNY 1.90 billion (y/y +20.52%)
• FY 2024 revenue: CNY 1.62 billion (y/y +57.21%)
• Revenue per employee: CNY 936,750 (2,028 employees)
• Price-to-Sales (P/S) ratio: 6.43
• Market capitalization: ~CNY 12.22 billion

• Top-line momentum: sequential quarterly growth plus healthy TTM and FY trends indicate expanding sales scale.
• Operating leverage potential: revenue per employee (CNY 936,750) suggests productivity that can support margin improvement if SG&A and R&D growth are controlled.
• Valuation context: P/S of 6.43 and market cap ≈ CNY 12.22 billion price the company as a growth-name-investors are paying a premium relative to sales.

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS) - Profitability Metrics

• Net profit margin: 26.25% - strong bottom-line conversion from revenues.
• Operating margin: 30.72% - indicates highly efficient core operations.
• EBITDA: CNY 662.75 million - solid proxy for operating cash generation.
• Earnings per share (TTM): CNY 1.61.
• Return on equity (ROE): 17.16% - effective deployment of shareholder capital.
• Dividend yield: 2.20% with a payout ratio of 1.61%.

• Implication: strong profitability metrics (high operating margin and net margin) combined with a healthy ROE suggest Sinopep-Allsino is converting R&D and operational investment into returns.
• Capital allocation: a 1.61% payout ratio implies management is retaining the bulk of earnings - potential for reinvestment-driven growth or future higher distributions.
• Valuation/returns cross-check: use EBITDA (CNY 662.75M) and EPS (CNY 1.61) when comparing EV/EBITDA and P/E multiples to sector peers.

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS) - Debt vs. Equity Structure

Key balance-sheet and cash-flow indicators show Sinopep-Allsino managing a moderate leverage profile while investing heavily in growth. Below are the principal figures that define its debt/equity posture and short-term liquidity.

• Debt-to-Equity Ratio: 82.43% (moderate leverage).
• Total Debt: CNY 2.58 billion.
• Net Cash Position (Net Debt): -CNY 1.50 billion (net debtor).
• Equity (Book Value): CNY 3.13 billion; Book Value per Share: CNY 9.84.
• Working Capital: CNY 693.33 million (adequate short-term liquidity).
• Operating Cash Flow: CNY 517.18 million (positive operational cash generation).
• Capital Expenditures (CapEx): CNY 1.46 billion (significant investment activity).

Practical implications for investors:

• The 82.43% debt-to-equity ratio signals a leverage level that is material but not excessive for a capital-intensive biotech/biopharma firm.
• Net debt of CNY 1.50bn against CNY 3.13bn equity yields a net debt-to-equity of ~47.9% (1.50 / 3.13), indicating manageable net leverage when considering equity backing.
• Positive operating cash flow (CNY 517.18m) supports debt servicing, but high CapEx (CNY 1.46bn) implies continued capital demands that may sustain borrowing or equity dilution pressure.
• Working capital of CNY 693.33m suggests sufficient short-term liquidity to cover routine obligations despite sizable long-term investments.

For the company's strategic context and stated priorities that interact with capital structure decisions, see: Mission Statement, Vision, & Core Values (2026) of Sinopep-Allsino Bio Pharmaceutical Co.,Ltd.

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS) Liquidity and Solvency

Sinopep-Allsino's recent balance sheet and coverage metrics present a snapshot of liquidity and solvency that investors should weigh when assessing near-term stability and long-term risk exposure. Key numeric indicators are summarized below and arranged for quick reference.

• Cash and cash equivalents: CNY 988.01 million
• Short-term investments: CNY 93 million
• Current ratio: ~1.5
• Quick ratio: ~1.2
• Interest coverage ratio: 5.5
• Altman Z-Score: 2.98
• Piotroski F-Score: 5

Contextual notes for investors:

• With nearly CNY 1.08 billion in combined cash and short-term investments, the company has tangible liquidity buffers for operational needs and opportunistic spending.
• Current and quick ratios above 1.0 indicate coverage of short-term obligations; however, the margins are not excessive, so working capital management remains important.
• An interest coverage ratio of 5.5 signals manageable debt servicing but warrants monitoring if earnings weaken.
• The Altman Z-Score of 2.98 sits below the "safe" threshold (usually >3.0), implying a moderate risk profile that could be sensitive to shocks.
• A Piotroski F-Score of 5 suggests neither a strong turnaround nor significant deterioration-an investor should combine this with trend analysis of profitability, margins, and cash flows.

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS) Valuation Analysis

• Price-to-Earnings (P/E): 24.59 - moderate premium to current earnings.
• Price-to-Book (P/B): 4.03 - market assigns a significant multiple to net assets.
• Beta: 0.44 - lower volatility than the broader market, suggesting defensive characteristics.
• 52-week price change: +0.42% - minimal net movement over the year, implying stability.
• 50-day MA: CNY 39.74; 200-day MA: CNY 39.51 - short- and long-term averages effectively aligned.
• RSI (14): 45.30 - neutral momentum, no clear overbought/oversold signal.

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS) - Risk Factors

Recent developments and core financial indicators point to elevated risk for Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. Investors should weigh regulatory, operational and balance-sheet exposures described below.

• Regulatory action: In July 2025 the company was fined CNY 47.4 million for inflating earnings and received a delisting warning.
• Index treatment: The stock was removed from Solactive-administered indices effective July 28, 2025, following the risk alert.
• Market reputation and liquidity risk stemming from the fine, warning and index removal.

• Operational risks: A Piotroski F-Score of 5 signals only average financial improvements (profitability, leverage, liquidity and operating efficiency metrics mixed).
• Financial leverage: Debt-to-equity at 82.43% increases sensitivity to margin pressure and rising interest rates.
• Bankruptcy probability: Altman Z-Score of 2.98 places the firm in a moderate-risk 'gray' zone, not safe from distress if conditions deteriorate.
• Governance and disclosure risk: The earnings-inflation sanction raises questions about internal controls, audit reliability and management incentives.
• Market access and liquidity risk: Index removal and delisting warning may accelerate outflows from passive and institutional holders.

Key risk drivers summarized:

• Regulatory scrutiny and sanctions (CNY 47.4M fine, delisting warning).
• Reduced market liquidity (Solactive index removal effective 2025-07-28).
• Moderate financial distress indicators (Altman Z-Score 2.98; Piotroski F-Score 5).
• Leverage-related vulnerability (debt-to-equity 82.43%).

For broader company background and context on ownership, mission and operations see: Sinopep-Allsino Bio Pharmaceutical Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS) - Growth Opportunities

• R&D intensity: R&D expenditure represented 11.83% of operating revenue in 2020, signaling heavy reinvestment into new drug discovery and development.
• Therapeutic focus: Strategic expansion into metabolic and antiviral drug portfolios targets sizeable and growing markets with significant unmet needs.
• Shareholder returns: A dividend of CNY 0.8 per share demonstrates a shareholder-friendly posture while retaining capital for R&D and capacity expansion.
• Market valuation and stability: Market capitalization of approximately CNY 13.9 billion and a beta of 0.515 suggest investor expectations of ongoing innovation with lower relative volatility.
• Vertical integration: Control over research, production, and technical services reduces dependence on third parties, supports margin capture, and accelerates commercialization timelines.